Finance
Gilead Sciences to Acquire Arcellx in $8 Billion Deal to Dominate Cell Therapy Market
Gilead Sciences has reached a definitive agreement to acquire biotech firm Arcellx for nearly $8 billion, marking a major consolidation in the oncology sector. The deal aims to bolster Gilead's pipeline of advanced cell therapies as competition among pharmaceutical giants intensifies in 2026.
February 24, 2026905 views
Score0
Enjoyed this story? Share it! 👇
Advertisement
Related Stories
Finance
Stellantis Records First Annual Loss in History Following 20 Billion Euro EV Writedown
1d ago
Finance
Imperial Petroleum Accelerates Fleet Expansion as Valuation Multiples Lag Behind Earnings
1d ago
Finance
Syngenta Prepares $10 Billion Hong Kong IPO for Second Quarter Launch
1d ago
Finance
Uber and Lyft Shares Surge as Trump Administration Scraps Independent Contractor Rule
1d ago
Comments (0)
Sign in to leave a comment.
No comments yet. Be the first to share your thoughts!